Starlix
nateglinide
Table of contents
Overview
The marketing authorisation for Starlix has been withdrawn at the request of the marketing-authorisation holder.
Authorisation details
| Product details | |
|---|---|
| Name |
Starlix
|
| Agency product number |
EMEA/H/C/000335
|
| Active substance |
nateglinide
|
| International non-proprietary name (INN) or common name |
nateglinide
|
| Therapeutic area (MeSH) |
Diabetes Mellitus, Type 2
|
| Anatomical therapeutic chemical (ATC) code |
A10BX03
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Novartis Europharm Limited
|
| Revision |
15
|
| Date of issue of marketing authorisation valid throughout the European Union |
03/04/2001
|
| Contact address |
Vista Building |
Product information
08/11/2021 Starlix - EMEA/H/C/000335 - IB/0040
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Drugs used in diabetes
Therapeutic indication
Nateglinide is indicated for combination therapy with metformin in type-2 diabetic patients inadequately controlled despite a maximally tolerated dose of metformin alone.